RAiN BioScience is a pharmaceutical startup company. Our mission is the development of a new generation of RNA-based pharmaceuticals for difficult-to-treat diseases.
Using RNA-targeting oligomers called Morpholinos, RAiN aspires to become a leader in developing innovative treatments for underserved medical conditions based on the principle of Antisense.
RAiN is differentiated from its competitors by its focus on the development of hybrid molecules that link Morpholino oligomers to proprietary cell-penetrating peptides. RAiN's peptides are specifically designed to promote delivery of the therapeutic oligomers into target cells while minimizing unwanted delivery into the kidney. This breakthrough technology allows the systematic development of Antisense therapeutics that offer superior efficacy and excellent safety profiles.